Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Yersinia pseudotuberculosis (Y. pseudotuberculosis) infection is an intestinal infectious disease comparable in importance as those with Campylobacter or Salmonella. Clinical symptoms of Y. pseudotuberculosis infection vary. In this report, we will describe the clinical symptoms and immunological conditions of the patients with Y. pseudotuberculosis infection, including 2 or our own cases. Case 1 was a 4 years old male infant admitted to the hospital with major complaints of fever, diarrhea, and vomiting. Kawasaki disease was the most suspected diagnosis from the clinical viewpoint. These symptoms improved by symptomatic treatments. Serum examination during hospitalisation revealed the infection of Y. pseudotuberculosis 4a. Case 2 was a 7 months old male baby with psychomotor developmental delay. The patient was admitted to hospital with major complaints of fever and eruptions. The patient was diagnosed to have a severe infectious disorder based on the clinical symptoms and findings of laboratory tests. Treatments with antibiotics improved the conditions. Serum examination during hospitalisation also revealed the Y. pseudotuberculosis 5a infection. Both of these cases showed decreased cellular immunity during the acute phase of the infection which was normalized with the improvement in clinical conditions. It was thus suggested that Y. pseudotuberculosis had a possibility to influence the cellular immunity of hosts transiently but significantly.
 ...
PMID:[Two cases of Yersinia pseudotuberculosis infection in children]. 228 88

The effectiveness and tolerance of alizapride and metopimazine used to treat vomiting induced by acute infectious diseases were evaluated in 47 infants and children seen in five hospitals. Patients were randomized to alizapride (n = 23) or metopimazine (n = 24). Medications were given orally (drops) for 3 to 5 days. All the patients were monitored until the end of the study period. Effectiveness was excellent or good in both groups with no statistically significant difference. Clinical tolerance was outstanding in both groups; one patient in the alizapride group exhibited transient, mild drowsiness after the doses. This study confirms the good risk/benefit ratio of alizapride in the treatment of emesis in infants and children.
 ...
PMID:[Treatment of vomiting in infants and children induced by acute infectious pathology. A comparative study of alizapride versus metopimazine]. 229 97

Oral ciprofloxacin in doses of 0.75 to 2 g daily for 8-16 (median 10) days was given as first-line treatment of 33 unselected episodes of CAPD-associated peritonitis in 20 patients. Treatment was well tolerated and effective, curing 25 episodes. Treatment was withdrawn in five episodes, four because of resistant organisms and in the other because of vomiting. Infection relapsed twice in one patient during follow-up and one patient had persistence of the infecting organism (Pseudomonas aeruginosa) despite clinical improvement. Plasma and dialysate ciprofloxacin levels ranged from 1 to 8 mg/l. Assay between days 2 and 4 of treatment indicated the ciprofloxacin steady state concentration. If this proves to be greater than 7 mg/l the dose may be reduced and if less than 2 mg/l the dose should be increased. Overall a single course of oral ciprofloxacin was 76% successful as a first-line treatment for CAPD-associated peritonitis, caused by a wide range of organisms.
 ...
PMID:Oral ciprofloxacin in the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. 213 40

A case of intestinal cryptosporidiosis in an eight-year-old boy is presented. The patient became ill during a visit to a farm where diarrhoea in newborn calves is a recurrent problem. Furthermore, on that farm kittens periodically suffer from diarrhoea and failure to thrive. Oocysts of Cryptosporidium sp. were identified in the stool of the patient, and in the stool of the cat he had contact with. At that time the calves were not infected. The patient's gastrointestinal symptomatology consisted of severe diarrhoea, vomiting, colics and moderate dehydration, and was preceded by coughing.
Infection
PMID:Intestinal cryptosporidiosis acquired from a cat. 236 71

Fifty-five ambulatory children with early culture-proven pertussis were treated for two weeks either with erythromycin ethylsuccinate (n = 28) (50-80 mg/kg/day in three doses during meals) or with co-trimoxazole (n = 27) (6-10 mg trimethoprim/kg/day in two doses after meals). After completion of treatment, all patients in the erythromycin group were culture-negative, while in the co-trimoxazole group one child was still culture-positive. In this case vomiting may have played a role. Both agents appear to be able to eradicate Bordetella pertussis from the nasopharynx of patients with early whooping cough.
Infection
PMID:Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis. 254 64

Rotavirus infection and associated symptoms were studied prospectively from 1976 through 1981 in a 10% sample of families in Tecumseh, Michigan. Infection was determined using an antibody enzyme-linked immunosorbent assay (ELISA) method designed for use with large numbers of sera collected semiannually. Illness was identified from symptoms ascertained weekly by telephone. Risks of infection during a rotavirus season varied from 4.8% in 1978 to 9.2% in 1980. Risks were 20.6% in the under two years age group and decreased progressively with age to 3.6% in individuals aged 45 years or over. Preschool children accounted for less than 20% of the infections in the population of reference. Infection was associated with diarrhea in the first two years of life and with both diarrhea and vomiting later in life. There was no evidence for association of rotavirus infection with a gastrointestinal-respiratory syndrome. The pathogenicity of infection, the protectiveness of antibody, and the socioeconomic correlates of infection showed marked changes from year to year. In 1978, there was a dramatically higher pathogenicity and a greater protectiveness of ELISA measured antibody than in other years. There was also a dramatic reversal in the socioeconomic relations of infection from 1977 to 1978. Taken together, these findings suggest that different rotaviruses might have predominated in these years.
 ...
PMID:The Tecumseh Study. XV: Rotavirus infection and pathogenicity. 254 88

Thirteen 3-week-old pigs that had been allowed to nurse for the first 16 to 18 hours after birth were orally inoculated with 1 x 10(6.5) TCID50 of porcine rotavirus. All developed diarrhea, anorexia, and vomiting by postinoculation (PI) hour 30. These signs had abated by PI day 6. Villus blunting in the small intestine was most severe in the jejunum and ileum of pigs euthanatized between PI days 3 and 5. Villi had returned to nearly normal length by PI day 6, although fused villi were seen in a few locations in the distal portion of the jejunum and in the ileum. Virus was detected in the feces of inoculated pigs by isolation in cell cultures and by electron microscopy during the 7-day course of the experiment. There was 1 extraintestinal virus isolation from the lung of 1 pig at PI day 2. Infection and disease developed in the presence of serum-neutralizing antibody obtained by nursing seropositive sows. There was no significant change in neutralizing antibody titers in the 3-week-old pigs over the course of the experiment. In this experimental work, a model to study rotavirus infection in 3-week-old pigs has been developed.
 ...
PMID:Experimental rotavirus infection in three-week-old pigs. 255 35

Three male infants with vomiting, dehydration, hyponatremia, hyperkalemia and metabolic acidosis were found to have vesicoureteral reflux (VUR) and urinary tract infection. Two were initially thought to have the salt-losing form of congenital adrenal hyperplasia. Although prompt diagnosis of this potentially fatal condition is critical, its mimicry by urosepsis in infants with VUR is actually more common. Infection probably causes unresponsiveness of the distal renal tubules to aldosterone.
 ...
PMID:Urosepsis in infants with vesicoureteral reflux masquerading as the salt-losing type of congenital adrenal hyperplasia. 267 49

Dry syrup and tablet of newly developed cefpodoxime proxetil (CS-807, CPDX-PR) was investigated in the departments of pediatrics of 17 institutes and their related hospitals. 1. Pharmacokinetics of CPDX-PR in pediatrics were investigated. Peak blood levels of CPDX at dose levels of 3 mg/kg and 6 mg/kg were 2.24 +/- 0.21 and 4.68 +/- 0.54 micrograms/ml, respectively, in fasting and 1.65 +/- 0.07 and 3.71 +/- 0.41 micrograms/ml, respectively, after meal. Urinary recovery rates in 6 hours were 31.2 +/- 2.2% of dose in average. 2. Clinical efficacies of CPDX-PR on various infectious diseases were studied in 748 cases. Clinical efficacy rate in 499 cases with causative bacteria isolated was 94.6%: efficacy rates for individual infections were 96.8% (120/124) for tonsillitis, 96.0% (96/100) for urinary tract infection, 93.5% (58/62) for pneumonia, 92.4% (61/66) for impetigo, 100% (32/32) for scarler fever and 93.2% for pharyngitis or laryngitis. Bacteriological eradication rate for Gram-positive organisms was 91.0% (244/268); and for Gram-negative organisms, 89.7% (210/234). The clinical efficacy rate for cases which were non-responsive to previous antibiotic therapy was 88.1% (74/84). 3. Side effects and clinical laboratory findings were investigated in 779 cases. Two each of vomiting, loose stool and rash, 10 of diarrhea and 1 of diarrhea associated with candidiasis were reported, but no serious side effects were noted. There was no serious laboratory test abnormality except slight elevations of eosinophile, platelet, transaminase or prolongation of prothrombin time, totalling 34 occurrences.
 ...
PMID:[Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields]. 268 63

Pharmacokinetic, bacteriological and clinical studies on cefpodoxime proxetil (CPDX-PR, CS-807), a newly developed oral cephem, were carried out in the treatment of infectious diseases in the field of pediatrics. 1. Since CPDX demonstrates very powerful antimicrobial actions against such Gram-negative bacilli as Escherichia coli, Salmonella sp., Klebsiella pneumoniae and Serratia sp., such Gram-positive cocci as Streptococcus pyogenes and Streptococcus pneumoniae, and beta-lactamase producing Branhamella catarrhalis and Haemophilus influenzae, this drug was thought to be useful for the treatment of pediatric infectious diseases when main causative bacteria in the field of pediatrics were taken into account. 2. When changes in blood and urine concentrations of CPDX following the administration of this drug at 3.7 mg/kg before meal were determined, Cmax and T1/2 were found to be 2.98 micrograms/ml at 2-hour and 1.73 hours, respectively; an urinary excretion rate in the first 6 hours and a maximum urine concentration were 32.5% and 52 micrograms/ml, respectively. 3. Clinically, 8 of 8 patients with the upper respiratory tract infections (100%), 28 of 29 patients with bronchitis and/or pneumonia (96.6%), 3 of 4 patients with otitis media (75%), 2 of 2 patients with sinusitis (100%), 3 of 3 patients with the skin soft tissue infections (100%), 1 of 1 patient with bacterial enteritis (100%) and 11 of 14 patients with urinary tract infections (78.6%) responded well to the treatment with CPDX-PR, showing a 91.8% efficacy rate in all the patients treated. 4. Bacteriologically, Staphylococcus aureus, Staphylococcus epidermidis, S. pyogenes, S. pneumoniae, E. faecalis, B. catarrhalis, H. influenzae, E. coli and Salmonella typhimurium were all eradicated from 5, 1, 4, 6, 1, 5, 5, 11 and 1 patient, respectively. An eradication rate in all the patients examined was 97.5% (39/40). 5. Gastrointestinal symptoms appeared as side effects in 2 of 71 patients (vomiting in 1 and diarrhea in 1), hence, an incidence of side effects was 2.8% (2/71). As for abnormal laboratory findings, eosinophilia, thrombocytosis and increases in GOT and GPT were observed in 3 of 39 patients examined (7.7%), 1 of 39 patients (2.6%) and 2 of 34 patients (5.9%), respectively. In addition, we also examined the effect of the drug on the hemostatic system, but found no changes upon the treatment. Based on these results, it appeared that CPDX-PR was a useful and safe drug in treatment of infectious diseases in the field of pediatrics when administered 2-3 times a day at a dose of 3-6 mg/kg.
 ...
PMID:[Pharmacokinetic, bacteriological and clinical studies on cefpodoxime proxetil in the field of pediatrics]. 281 Jul 29


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>